DNTH – dianthus therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) was upgraded by analysts at Raymond James to a "moderate buy" rating.
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its price target raised by analysts at Oppenheimer Holdings Inc. from $48.00 to $52.00. They now have an "outperform" rating on the stock.
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its price target raised by analysts at Raymond James from $51.00 to $56.00. They now have an "outperform" rating on the stock.
Form 8-K Dianthus Therapeutics, For: Dec 12
Form SC 13D/A Dianthus Therapeutics, Filed by: Avidity Partners Management LP
Form SC 13G Dianthus Therapeutics, Filed by: TCG Crossover GP II, LLC
Form SC 13G/A Dianthus Therapeutics, Filed by: 5AM Partners VII, LLC
Form SC 13G/A Dianthus Therapeutics, Filed by: Venrock Healthcare Capital Partners III, L.P.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.